Education
About Us
Working with TipRanks
Follow Us
Parnell Pharmaceuticals Holdings (PARNF)
OTHER OTC:PARNF
PARNF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.05 - $0.35
Previous CloseN/A
Volume45.20K
Average Volume (3M)N/A
Market Cap
$1.45M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta9590.54
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding18,146,000
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.32
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
1.51% Other Institutional Investors
98.49% Public Companies and
Individual Investors
PARNF FAQ
What was Parnell Pharmaceuticals Holdings’s price range in the past 12 months?
Parnell Pharmaceuticals Holdings lowest stock price was $0.05 and its highest was $0.35 in the past 12 months.
What is Parnell Pharmaceuticals Holdings’s market cap?
Parnell Pharmaceuticals Holdings’s market cap is $1.45M.
When is Parnell Pharmaceuticals Holdings’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Parnell Pharmaceuticals Holdings’s earnings last quarter?
Parnell Pharmaceuticals Holdings released its earnings results on Oct 14, 2019. The company reported -$0.059 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.059.
Is Parnell Pharmaceuticals Holdings overvalued?
According to Wall Street analysts Parnell Pharmaceuticals Holdings’s price is currently Overvalued.
Does Parnell Pharmaceuticals Holdings pay dividends?
Parnell Pharmaceuticals Holdings does not currently pay dividends.
What is Parnell Pharmaceuticals Holdings’s EPS estimate?
Parnell Pharmaceuticals Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Parnell Pharmaceuticals Holdings have?
Parnell Pharmaceuticals Holdings has 18,146,000 shares outstanding.
What happened to Parnell Pharmaceuticals Holdings’s price movement after its last earnings report?
Parnell Pharmaceuticals Holdings reported an EPS of -$0.059 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Parnell Pharmaceuticals Holdings?
Currently, no hedge funds are holding shares in PARNF
Company Description
Parnell Pharmaceuticals Holdings
Parnell Pharmaceuticals Holdings Ltd, a commercial-stage pharmaceutical company, focuses on developing, manufacturing, and marketing animal pharmaceutical products worldwide. The company operates through four segments: Companion Animal, Production Animal - U.S., Production Animal - Rest of World, and Manufacturing Operations. It markets various products, including estroPLAN and GONAbreed reproductive hormone products for enhancing cattle breeding performance; Zydax for the treatment of osteoarthritis (OA) in dogs and horses; and Glyde, a nutraceutical product for the treatment of OA, as well as Parnell PROcept, which adds an additional injection of estroPLAN after the first injection. The company also offers mySYNCH, a digital tool to help veterinarians and producers optimize reproduction and maximize economic gains. Parnell Pharmaceuticals Holdings Ltd was incorporated in 2009 and is headquartered in Alexandria, Australia.
Salarius Pharmaceuticals
―
Aptevo Therapeutics
―
Virpax Pharmaceuticals
―
ZyVersa Therapeutics
―
Onconetix
―